{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:37:41Z","timestamp":1791005861928,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s11883-021-00962-z","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T13:23:51Z","timestamp":1631539431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis"],"prefix":"10.1007","volume":"23","author":[{"given":"Patricia","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Passi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher","family":"Modarressi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meshal","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archna","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-6303","authenticated-orcid":false,"given":"Daniel","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"962_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547\u201363.","journal-title":"Circ Res"},{"key":"962_CR2","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"key":"962_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"962_CR4","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1210\/jc.2011-3213","volume":"97","author":"L Berglund","year":"2012","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969\u201389.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR5","unstructured":"Carroll M, Kit B, Lacher D. Trends in elevated triglyceride in adults: United States, 2001\u20132012. NCHS Data Brief. 2015;198."},{"key":"962_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5339\/gcsp.2015.33","volume":"2015","author":"Y Aguib","year":"2015","unstructured":"Aguib Y, Al SJ. The Copenhagen City heart study (\u00d8sterbrounders\u00f8gelsen). Glob Cardiol Sci Pract. 2015;2015:33.","journal-title":"Glob Cardiol Sci Pract"},{"key":"962_CR7","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/js.2019-00129","volume":"3","author":"MI Esparza","year":"2019","unstructured":"Esparza MI, Li X, Adams-Huet B, Vasandani C, Vora A, Das SR, et al. Very severe hypertriglyceridemia in a large US county health care system: associated conditions and management. J Endocr Soc. 2019;3:1595\u2013607.","journal-title":"J Endocr Soc"},{"key":"962_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/archinte.161.3.397","volume":"161","author":"DECODE Study Group, the European Diabetes Epidemiology Group","year":"2001","unstructured":"DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397\u2013405.","journal-title":"Arch Intern Med"},{"key":"962_CR9","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR10","doi-asserted-by":"publisher","first-page":"E1676","DOI":"10.1210\/jc.2014-1878","volume":"99","author":"J Joseph","year":"2014","unstructured":"Joseph J, Shamburek RD, Cochran EK, Gorden P, Brown RJ. Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. J Clin Endocrinol Metab. 2014;99:E1676\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR11","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/hep.23593","volume":"51","author":"EK Speliotes","year":"2010","unstructured":"Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham heart study. Hepatology. 2010;51:1979\u201387.","journal-title":"Hepatology"},{"key":"962_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Investig. 2020;130:1453\u201360.","journal-title":"J Clin Investig"},{"key":"962_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","volume":"362","author":"KF Petersen","year":"2010","unstructured":"Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang X-M, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082\u20139.","journal-title":"N Engl J Med"},{"key":"962_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14:57\u201370.","journal-title":"Nat Rev Nephrol"},{"key":"962_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.3396","volume":"20","author":"LC Clement","year":"2014","unstructured":"Clement LC, Mac\u00e9 C, Avila-Casado C, Joles JA, Kersten S, Chugh SS. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med. 2014;20:37\u201346.","journal-title":"Nat Med"},{"key":"962_CR16","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1172\/JCI107017","volume":"51","author":"EA Nikkil\u00e4","year":"1972","unstructured":"Nikkil\u00e4 EA, Kekki M. Plasma triglyceride metabolism in thyroid disease. J Clin Invest. 1972;51:2103\u201314.","journal-title":"J Clin Invest"},{"key":"962_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.mcna.2012.01.012","volume":"96","author":"LH Duntas","year":"2012","unstructured":"Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96:269\u201381.","journal-title":"Med Clin North Am"},{"key":"962_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/8207056","volume":"2019","author":"L Yang","year":"2019","unstructured":"Yang L, Yin R, Wang Z, Wang X, Zhang Y, Zhao D. Circulating Angptl3 and Angptl8 are increased in patients with hypothyroidism. Biomed Res Int. 2019;2019:1\u20139.","journal-title":"Biomed Res Int"},{"key":"962_CR19","first-page":"2993","volume":"85","author":"MD Danese","year":"2000","unstructured":"Danese MD, Ladenson PW, Meinert CL, Powe NR. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature*. J Clin Endocrinol Metab. 2000;85:2993\u20133001.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1210\/jcem.87.4.8378","volume":"87","author":"N Caraccio","year":"2002","unstructured":"Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab. 2002;87:1533\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000314213","volume":"92","author":"G Arnaldi","year":"2010","unstructured":"Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing\u2019s syndrome. Neuroendocrinology. 2010;92:86\u201390.","journal-title":"Neuroendocrinology"},{"key":"962_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1677\/JOE-08-0054","volume":"197","author":"DP Macfarlane","year":"2008","unstructured":"Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197:189\u2013204.","journal-title":"J Endocrinol"},{"key":"962_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/0026-0495(75)90129-8","volume":"24","author":"EA Nikkil\u00e4","year":"1975","unstructured":"Nikkil\u00e4 EA, Pelkonen R. Serum lipids in acromegaly. Metabolism. 1975;24:829\u201338.","journal-title":"Metabolism"},{"key":"962_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/0026-0495(80)90112-2","volume":"29","author":"T Murase","year":"1980","unstructured":"Murase T, Yamada N, Ohsawa N, Kosaka K, Morita S, Yoshida S. Decline of postheparin plasma lipoprotein lipase in acromegalic patients. Metabolism. 1980;29:666\u201372.","journal-title":"Metabolism"},{"key":"962_CR25","doi-asserted-by":"publisher","first-page":"E269","DOI":"10.1152\/ajpendo.1986.250.3.E269","volume":"250","author":"I Hansen","year":"1986","unstructured":"Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol Endocrinol Metab. 1986;250:E269\u201373.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"962_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.numecd.2007.01.014","volume":"18","author":"I Agledahl","year":"2008","unstructured":"Agledahl I, Skj\u00e6rpe P-A, Hansen J-B, Svartberg J. Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Troms\u00f8 study. Nutr Metab Cardiovasc Dis. 2008;18:256\u201362.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"962_CR27","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.atherosclerosis.2014.05.443","volume":"235","author":"C Chrysohoou","year":"2014","unstructured":"Chrysohoou C, Pitsavos D, Panagiotakos D, Oikonomou E, Lazaros G, Metaxa V, et al. Low testosterone levels are associated with metabolic syndrome, through triggering hypertriglyceridemia and low grade inflammation in elderly men. Ikaria study. Atherosclerosis. 2014;235:e155.","journal-title":"Atherosclerosis"},{"key":"962_CR28","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1210\/jc.2007-1972","volume":"93","author":"FCW Wu","year":"2008","unstructured":"Wu FCW, Tajar A, Pye SR, Silman AJ, Finn JD, O\u2019Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the european male aging study. J Clin Endocrinol Metab. 2008;93:2737\u201345.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2265.1982.tb00731.x","volume":"16","author":"R Pelkonen","year":"1982","unstructured":"Pelkonen R, Nikkil\u00e4 EA, Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol. 1982;16:383\u201390.","journal-title":"Clin Endocrinol"},{"key":"962_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.7326\/0003-4819-111-4-288","volume":"111","author":"DS Oppenheim","year":"1989","unstructured":"Oppenheim DS. Elevated serum lipids in hypogonadal men with and without hyperprolactinemia. Ann Intern Med. 1989;111:288.","journal-title":"Ann Intern Med"},{"key":"962_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","volume":"12","author":"A Shibli-Rahhal","year":"2009","unstructured":"Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12:96\u2013104.","journal-title":"Pituitary"},{"key":"962_CR32","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1210\/jc.2002-021137","volume":"88","author":"C Ling","year":"2003","unstructured":"Ling C, Svensson L, Od\u00e9n B, Weijdeg\u00e5rd B, Ed\u00e9n B, Ed\u00e9n S, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003;88:1804\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.steroids.2011.12.002","volume":"77","author":"RA Wild","year":"2012","unstructured":"Wild RA. Dyslipidemia in PCOS. Steroids. 2012;77:295\u20139.","journal-title":"Steroids"},{"key":"962_CR34","first-page":"232","volume":"2","author":"CJ Alexander","year":"2009","unstructured":"Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2:232\u20139.","journal-title":"Rev Obstet Gynecol"},{"key":"962_CR35","doi-asserted-by":"crossref","unstructured":"Ghio A, Bertolotto A, Resi V, Volpe L, Di Cianni G. Triglyceride metabolism in pregnancy. Advances in Clinical Chemistry. Elsevier; 2011 [cited 2021 Apr 7]. p. 133\u201353. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780123870421000071.","DOI":"10.1016\/B978-0-12-387042-1.00007-1"},{"key":"962_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000242614","volume":"50","author":"RH Knopp","year":"1986","unstructured":"Knopp RH, Warth MR, Charles D, Childs M, Li JR, Mabuchi H, et al. Lipoprotein metabolism in pregnancy, fat transport to the fetus, and the effects of diabetes. Neonatology. 1986;50:297\u2013317.","journal-title":"Neonatology"},{"key":"962_CR37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1210\/jcem-64-4-704","volume":"64","author":"G Desoye","year":"1987","unstructured":"Desoye G, Schweditsch MO, Pfeiffer KP, Zechner R, Kostner GM. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum*. J Clin Endocrinol Metab. 1987;64:704\u201312.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR38","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.2337\/dc07-s202","volume":"30","author":"LA Barbour","year":"2007","unstructured":"Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30:S112-9.","journal-title":"Diabetes Care"},{"key":"962_CR39","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1210\/jc.2012-1250","volume":"97","author":"AS Goldberg","year":"2012","unstructured":"Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. J Clin Endocrinol Metab. 2012;97:2589\u201396.","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jacl.2020.05.082","volume":"14","author":"J Lewey","year":"2020","unstructured":"Lewey J, Nemiroff R, Soffer D. Improving identification and treatment of primary and secondary hyperlipidemia for young women at a large health system. J Clin Lipidol. 2020;14:597.","journal-title":"J Clin Lipidol"},{"key":"962_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1753495X15594082","volume":"8","author":"B Wong","year":"2015","unstructured":"Wong B, Ooi TC, Keely E. Severe gestational hypertriglyceridemia: a practical approach for clinicians. Obstet Med. 2015;8:158\u201367.","journal-title":"Obstet Med"},{"key":"962_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11892-018-1008-2","volume":"18","author":"LA Barbour","year":"2018","unstructured":"Barbour LA, Hernandez TL. Maternal non-glycemic contributors to fetal growth in obesity and gestational diabetes: spotlight on lipids. Curr Diab Rep. 2018;18:37.","journal-title":"Curr Diab Rep"},{"key":"962_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0025-7125(16)30179-1","volume":"78","author":"NJ Stone","year":"1994","unstructured":"Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am. 1994;78:117\u201341.","journal-title":"Med Clin North Am"},{"key":"962_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/0026-0495(75)90078-5","volume":"24","author":"CJ Glueck","year":"1975","unstructured":"Glueck CJ, Fallat RW, Scheel D. Effects of estrogenic compounds on triglyceride kinetics. Metabolism. 1975;24:537\u201345.","journal-title":"Metabolism"},{"key":"962_CR45","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJM199110243251702","volume":"325","author":"BW Walsh","year":"1991","unstructured":"Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196\u2013204.","journal-title":"N Engl J Med"},{"key":"962_CR46","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","volume":"14","author":"EE Brown","year":"2020","unstructured":"\u2022 Brown EE, Sturm AC, Cuchel M, Braun LT, Duell PB, Underberg JA, et al. Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association. J Clin Lipidol. 2020;14:398\u2013413. An important review of the uses of genetic testing for lipid disorders, and specific evidence based recommendations when there is HTG.","journal-title":"J Clin Lipidol"},{"key":"962_CR47","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","volume":"275","author":"P Moulin","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, Arca M, Cefal\u00f9 AB, Noto D, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score.\u201d Atherosclerosis. 2018;275:265\u201372.","journal-title":"Atherosclerosis"},{"key":"962_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MED.0000000000000316","volume":"24","author":"C Koopal","year":"2017","unstructured":"Koopal C, Marais AD, Visseren FLJ. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. Curr Opin Endocrinol Diabetes Obes. 2017;24:133\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"962_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3109\/10408363.2013.870526","volume":"51","author":"AD Marais","year":"2014","unstructured":"Marais AD, Solomon GaE, Blom DJ. Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E. Crit Rev Clin Lab Sci. 2014;51:46\u201362.","journal-title":"Crit Rev Clin Lab Sci."},{"key":"962_CR50","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287.","journal-title":"JAMA Cardiol"},{"key":"962_CR51","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4158\/EP-2018-0157","volume":"24","author":"JM Falko","year":"2018","unstructured":"Falko JM. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. Endocr Pract. 2018;24:756\u201363.","journal-title":"Endocr Pract"},{"key":"962_CR52","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1161\/ATVBAHA.119.313401","volume":"39","author":"L D\u2019Erasmo","year":"2019","unstructured":"D\u2019Erasmo L, Di Costanzo A, Cassandra F, Minicocci I, Polito L, Montali A, et al. Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes. ATVB. 2019;39:2531\u201341.","journal-title":"ATVB"},{"key":"962_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0022-2275(20)38008-1","volume":"24","author":"JD Brunzell","year":"1983","unstructured":"Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res. 1983;24:147\u201355.","journal-title":"J Lipid Res"},{"key":"962_CR54","first-page":"877","volume":"3","author":"A Gaddi","year":"2007","unstructured":"Gaddi A, Cicero AFG, Odoo FO, Poli AA, Paoletti R, Atherosclerosis and metabolic diseases study group. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3:877\u201386.","journal-title":"Vasc Health Risk Manag."},{"key":"962_CR55","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/iub.2073","volume":"71","author":"E Taghizadeh","year":"2019","unstructured":"Taghizadeh E, Esfehani RJ, Sahebkar A, Parizadeh SM, Rostami D, Mirinezhad M, et al. Familial combined hyperlipidemia: an overview of the underlying molecular mechanisms and therapeutic strategies. IUBMB Life. 2019;71:1221\u20139.","journal-title":"IUBMB Life"},{"key":"962_CR56","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"962_CR57","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345\u201352.","journal-title":"Nat Genet"},{"key":"962_CR58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","volume":"18","author":"Y Fei","year":"2019","unstructured":"Fei Y, Tsoi M-F, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18:112.","journal-title":"Cardiovasc Diabetol"},{"key":"962_CR59","doi-asserted-by":"crossref","unstructured":"Arca M, Veronesi C, D\u2019Erasmo L, Borghi C, Colivicchi F, De Ferrari GM, et al. Association of hypertriglyceridemia with all\u2010cause mortality and atherosclerotic cardiovascular events in a low\u2010risk Italian population: the TG\u2010REAL retrospective cohort analysis. JAHA. 2020 [cited 2021 Apr 7];9. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.119.015801.","DOI":"10.1161\/JAHA.119.015801"},{"key":"962_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/2013.jamainternmed.477","volume":"173","author":"MJ Murphy","year":"2013","unstructured":"Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med. 2013;173:162.","journal-title":"JAMA Intern Med"},{"key":"962_CR61","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosissup.2010.03.004","volume":"11","author":"D Gaudet","year":"2010","unstructured":"Gaudet D, de Wal J, Tremblay K, D\u00e9ry S, van Deventer S, Freidig A, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl. 2010;11:55\u201360.","journal-title":"Atheroscler Suppl"},{"key":"962_CR62","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1503\/cmaj.060963","volume":"176","author":"G Yuan","year":"2007","unstructured":"Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. Can Med Assoc J. 2007;176:1113\u201320.","journal-title":"Can Med Assoc J"},{"key":"962_CR63","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","volume":"25","author":"P Valdivielso","year":"2014","unstructured":"Valdivielso P, Ram\u00edrez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25:689\u201394.","journal-title":"Eur J Intern Med"},{"key":"962_CR64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jacl.2020.11.010","volume":"15","author":"KM Gonzales","year":"2021","unstructured":"Gonzales KM, Donato LJ, Shah P, Simha V. Measurement of apolipoprotein B levels helps in the identification of patients at risk for hypertriglyceridemic pancreatitis. J Clin Lipidol. 2021;15:97\u2013103.","journal-title":"J Clin Lipidol"},{"key":"962_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4103\/1947-2714.168657","volume":"7","author":"C Shenoy","year":"2015","unstructured":"Shenoy C, Shenoy M, Rao G. Dyslipidemia in dermatological disorders. North Am J Med Sci. 2015;7:421.","journal-title":"North Am J Med Sci"},{"key":"962_CR66","unstructured":"Vanessa Ngan, Staff Writer; Dr Amy Stanway, Dermatology Registrar, Nottingham, United Kingdom, 2005. Xanthoma. 2005. Available from: https:\/\/dermnetnz.org\/topics\/xanthoma\/."},{"key":"962_CR67","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14779072.2017.1311786","volume":"15","author":"M Davidson","year":"2017","unstructured":"Davidson M, Stevenson M, Hsieh A, Ahmad Z, Crowson C, Witztum JL. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. Expert Rev Cardiovasc Ther. 2017;15:415\u201323.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"962_CR68","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292\u2013333.","journal-title":"Circulation"},{"key":"962_CR69","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archinternmed.2008.599","volume":"169","author":"ES Ford","year":"2009","unstructured":"Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169:572.","journal-title":"Arch Intern Med"},{"key":"962_CR70","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jacl.2013.04.001","volume":"7","author":"HE Bays","year":"2013","unstructured":"Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:304\u201383.","journal-title":"J Clin Lipidol"},{"key":"962_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacl.2015.09.002","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National lipid association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol. 2015;9:1-S122.e1.","journal-title":"J Clin Lipidol"},{"key":"962_CR72","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","volume":"77","author":"RP Mensink","year":"2003","unstructured":"Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146\u201355.","journal-title":"Am J Clin Nutr"},{"key":"962_CR73","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.109.192627","volume":"120","author":"RK Johnson","year":"2009","unstructured":"Johnson RK, Appel LJ, Brands M, Howard BV, Lefevre M, Lustig RH, et al. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2009;120:1011\u201320.","journal-title":"Circulation"},{"key":"962_CR74","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jacl.2019.08.003","volume":"13","author":"CF Kirkpatrick","year":"2019","unstructured":"Kirkpatrick CF, Bolick JP, Kris-Etherton PM, Sikand G, Aspry KE, Soffer DE, et al. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: a scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. J Clin Lipidol. 2019;13:689-711.e1.","journal-title":"J Clin Lipidol"},{"key":"962_CR75","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","volume":"12","author":"L Williams","year":"2018","unstructured":"Williams L, Rhodes KS, Karmally W, Welstead LA, Alexander L, Sutton L. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. J Clin Lipidol. 2018;12:908\u201319.","journal-title":"J Clin Lipidol"},{"key":"962_CR76","unstructured":"When Your Triglycerides Are Over 1,000 mg\/dL. https:\/\/www.lipid.org\/. Available from: https:\/\/www.lipid.org\/sites\/default\/files\/when_your_tgs_are_over_1000_mgdl.pdf."},{"key":"962_CR77","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","volume":"13","author":"CE Orringer","year":"2019","unstructured":"Orringer CE, Jacobson TA, Maki KC. National lipid association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13:860\u201372.","journal-title":"J Clin Lipidol"},{"key":"962_CR78","first-page":"CD003177","volume":"11","author":"AS Abdelhamid","year":"2018","unstructured":"Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;11:CD003177.","journal-title":"Cochrane Database Syst Rev."},{"key":"962_CR79","first-page":"843","volume":"1821","author":"GC Shearer","year":"2012","unstructured":"Shearer GC, Savinova OV, Harris WS. Fish oil \u2014 how does it reduce plasma triglycerides? Biochim Biophys Acta (BBA) Mol Cell Biol Lipids. 2012;1821:843\u201351.","journal-title":"Biochim Biophys Acta (BBA) Mol Cell Biol Lipids."},{"key":"962_CR80","doi-asserted-by":"crossref","unstructured":"Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019 [cited 2021 Apr 11];140. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000709.","DOI":"10.1161\/CIR.0000000000000709"},{"key":"962_CR81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"\u2022\u2022 Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322. RCT demonstrating significant CVD risk reduction with high dose EPA (non-statin) added to optimal medical therapy for at-risk individuals with HTG.","journal-title":"N Engl J Med."},{"key":"962_CR82","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"\u2022\u2022 Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268. RCT failing to show benefit from high dose O3FA (EPA plus DHA) added to optimal medical therapy for at-risk individuals with HTG.","journal-title":"JAMA."},{"key":"962_CR83","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088\u201393.","journal-title":"Circulation"},{"key":"962_CR84","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11883-016-0571-8","volume":"18","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Morris PB. Gemfibrozil in combination with statins\u2014is it really contraindicated? Curr Atheroscler Rep. 2016;18:18.","journal-title":"Curr Atheroscler Rep"},{"key":"962_CR85","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237\u201345.","journal-title":"N Engl J Med"},{"key":"962_CR86","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410\u20138.","journal-title":"N Engl J Med"},{"key":"962_CR87","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. The Lancet. 2014;384:626\u201335.","journal-title":"The Lancet"},{"key":"962_CR88","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144\u201352.","journal-title":"Atherosclerosis"},{"key":"962_CR89","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018;206:80\u201393.","journal-title":"Am Heart J"},{"key":"962_CR90","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-014-0339-9","volume":"75","author":"LJ Scott","year":"2015","unstructured":"Scott LJ. Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Drugs. 2015;75:175\u201382.","journal-title":"Drugs"},{"key":"962_CR91","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.atherosclerosis.2014.05.007","volume":"235","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Stroes E, Bruno M, Andersen M, Petry H, Meyer C. Gene therapy with alipogene tiparvovec (glybera\u00ae) for the prevention of LPLD induced pancreatitis: follow-up data suggests long-term clinical benefit. Atherosclerosis. 2014;235:e13.","journal-title":"Atherosclerosis."},{"key":"962_CR92","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342.","journal-title":"N Engl J Med"},{"key":"962_CR93","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41:3936\u201345.","journal-title":"Eur Heart J"},{"key":"962_CR94","unstructured":"A dose-ranging study with vupanorsen (TRANSLATE-TIMI 70). Clinicaltrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04516291."},{"key":"962_CR95","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Banerjee P, Hamon S, Chan K-C, Bouzelmat A, Sasiela WJ, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140:470\u201386.","journal-title":"Circulation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-021-00962-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-021-00962-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-021-00962-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:09:16Z","timestamp":1744193356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-021-00962-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":95,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1007\/s11883-021-00962-z","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"24 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Soffer reports consultant for Akcea Therapeutics, Novartis; and investigator in clinical trials with Ionis, Amgen Inc., AstraZeneca, Ionis, Novartis, Pfizer, Regeneron, and REGENXBIO. Dr. Modarressi reports Speakers\u2019 Bureau for AstraZeneca. Dr. Bajaj reports investigator in clinical trials with Amgen Inc., Ionis, Novartis, Pfizer, Regeneron, and REGENXBIO. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"72"}}